NR and Parkinson’s Disease: NADPARK, NR-SAFE and NOPARK

NR has not been shown to slow Parkinson's disease progression. The 2026 phase III NOPARK trial tested 500 mg twice daily for 52 weeks and did not support a disease-modifying benefit. Its primary clinical difference favored placebo. That later result should lead an up-to-date discussion, rather than being overshadowed by encouraging early biomarker studies. ^[1]

NADPARK and NR-SAFE remain scientifically useful: they investigated target engagement and short-term safety. Their findings do not establish that NR is an effective Parkinson's treatment, and they should now be interpreted alongside the larger phase III outcome. ^{[2] [3]}

NOPARK: the result that changes the clinical interpretation

NOPARK randomized 410 people with early-stage Parkinson's disease, with 393 included in the primary analysis. Participants received NR 500 mg twice daily or placebo for 52 weeks. ^[1]

The adjusted between-group difference on MDS-UPDRS parts I–III was 2.72 points in favor of placebo. The reported difference was statistically significant but below the stated threshold for clinical importance. Four of five key secondary outcomes were null, while the nonmotor symptom measure also favored placebo.

This is not evidence that NR slowed progression. It also should not be exaggerated into proof that every NR user will experience clinically important deterioration. The appropriate conclusion concerns the tested population, regimen, duration and outcomes: the trial did not support the intended disease-modifying benefit.

A difference can be statistically detectable while smaller than a clinically important threshold. Both facts matter. Reporting only “not clinically important” would conceal the unfavorable direction, while reporting only “worsened Parkinson's” would overstate what the measured difference establishes.

The research sequence at a glance

These reports are not four equivalent independent efficacy successes. One is a companion analysis, two are early safety/target-engagement work, and the later phase III trial addresses the clinical question more directly. ^{[2] [4] [3] [1]}

What NADPARK originally showed

NADPARK investigated 30 newly diagnosed, treatment-naive people over 30 days. NR increased cerebral NAD-related signals in a variable subset and was associated with metabolic and inflammatory changes. Exploratory clinical findings helped motivate further research. ^[2]

The small size, short duration and phase I purpose are essential context. Target engagement demonstrates that the intervention can affect a relevant biological system. It does not show that the effect is sufficient to slow a progressive neurodegenerative disease.

If a person whose biomarker changes also improves on an exploratory measure, that observation may suggest a hypothesis. It does not establish a validated responder-selection test or prove that future patients can be identified and treated successfully using a commercial NAD+ assay.

What NR-SAFE adds

NR-SAFE tested 1.5 g twice daily for four weeks in 20 people with Parkinson's disease. It examined safety and metabolic measures rather than providing definitive evidence of slowed progression. ^[3]

The trial reported short-term high-dose tolerability and changes in the NAD metabolome. It also described an initial homocysteine rise without depletion of the measured methyl-donor pool. The study did not include TMG co-supplementation or randomize participants to NR with versus without TMG.

Those details are useful for the safety and methylation questions. They do not establish an optimal treatment dose, indefinite high-dose safety or a reason to escalate after the phase III efficacy result. A larger amount needs its own efficacy evidence, not merely a rationale that more target engagement must be better.

Why early promise and a later null trial can coexist

Early trials are designed to determine feasibility, tolerability, exposure and whether a larger study is worth doing. Their participants and endpoints may be selected differently from a later clinical trial. Small samples can also produce unstable exploratory effects.

A phase III outcome can therefore be disappointing without making the early work meaningless. The research program tested a plausible hypothesis more rigorously and obtained an answer that changes the clinical conclusion.

The wrong response is to treat every early biomarker change as a successful treatment result and explain away the later primary endpoint. The more useful response is to report the full sequence and investigate why biological activity did not translate into the intended benefit.

What MDS-UPDRS does and does not mean

MDS-UPDRS measures several domains of Parkinson's-related symptoms and function. Parts I–III combine nonmotor experiences, motor experiences of daily living and a motor examination. It is a clinical scale, not a direct measurement of every biological process underlying neuronal loss.

A prespecified difference on that scale is relevant to the trial's treatment question. Its magnitude, confidence interval, assessment conditions, missing data and clinical-importance threshold all affect interpretation.

The 2.72-point adjusted difference favoring placebo should therefore be reported with its context. It does not establish a universal individual response or settle every other NR indication, but it does not support marketing this regimen as disease-modifying Parkinson's therapy. ^[1]

Does higher NAD+ still count as success?

It counts as target engagement if the relevant assay demonstrates it. It does not count as a clinical treatment success when the intended progression endpoint is not improved.

NAD+ biology may remain relevant to Parkinson's disease, and future research may examine different approaches. That scientific possibility is separate from recommending a currently unproven supplement regimen to patients.

Blood NAD+, brain spectroscopy and symptom scales also represent different measurements. A favorable result in one should not silently replace an unfavorable or null result in another. Our NR benefits guide applies the same distinction across other clinical settings.

Combination metabolic activators are a different intervention

A phase II study of combined metabolic activators in Parkinson's disease used NR with serine, NAC and carnitine tartrate. It reported cognitive and molecular findings in a small randomized study. ^[5]

That intervention cannot establish the independent effect of NR, because several active components were supplied together. It also does not overturn NOPARK's result for the NR-only regimen simply because both studies involve NR.

The relevant comparison would need to identify the whole formula, population, outcome and control. A retail combination with different amounts cannot inherit the research result from ingredient-name overlap. See the combination review for that distinction.

Can NR replace or reduce Parkinson's medicines?

The evidence discussed here does not support replacing established Parkinson's care with NR. Decisions about dopaminergic treatment, exercise, rehabilitation and symptom management belong within the clinical care plan.

A supplement should not be used as a reason to stop or reduce medicines independently. Likewise, a clinician should know about the full formula, because a product marketed as an NR supplement may contain additional active ingredients.

The safety guide discusses the limits of interaction and long-term evidence. A label claiming “no known interactions” is not a complete assessment of every individual's regimen.

Is there a recommended Parkinson's NR protocol?

There is no established self-treatment protocol that follows from these studies. The amounts in NADPARK, NR-SAFE and NOPARK describe research exposures with eligibility criteria and monitoring, not interchangeable consumer options.

The dosage guide preserves that distinction. It also explains why a supervised high-dose safety study cannot justify an indefinite high-dose routine, and why a failed efficacy outcome should not prompt automatic escalation.

For someone already taking NR, the practical step is to discuss the actual product, amount, purpose and new evidence with the treating team. The discussion can consider individual circumstances without assuming either a proven benefit or a predetermined individual harm.

What future evidence would change the answer?

A different regimen, subgroup hypothesis or formulation would need prospective evidence with meaningful clinical outcomes and appropriate controls. Retrospective responder stories, isolated biomarker changes or a mechanistic explanation would not be enough by themselves.

Any proposed subgroup should be defined and tested in a way that avoids selecting favorable results after the fact. Longer-term safety and patient-relevant benefit would both matter. The phase III finding provides a benchmark that future claims must address directly.

The NR Data Center links the original reports and companion analyses. The current conclusion is clear for clinical decision-making: NR research has demonstrated biological activity, while the 2026 phase III result does not support using the tested regimen as a disease-modifying Parkinson's treatment.